# Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

> **NCT02441803** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Clofarabine
- **RADIATION:** Total Body Irradiation (TBI)
- **DRUG:** Thymoglobulin
- **BIOLOGICAL:** Stem Cell Infusion
- **DRUG:** Cyclophosphamide
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Decitabine
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT02441803
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2020-09-22
- **Final completion:** 2021-09-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441803, "Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02441803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*